Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Isabel Lucena

Showing results (71-80 of 152) with videos related to

Pageof 16
Sort By:
Expert Opinion on Drug Metabolism & Toxicology|September 15, 2022
Modeling drug-induced liver injury: current status and future prospectsDaniel E Di Zeo-Sánchez, Antonio Segovia-Zafra, Gonzalo Matilla-Cabello, et al.
Hepatology (Baltimore, Md.)|June 16, 2011
The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injuryAyako Suzuki, Elizabeth M Brunt, David E Kleiner, et al.
Plos One|July 23, 2013
HLA alleles influence the clinical signature of amoxicillin-clavulanate hepatotoxicityCamilla Stephens, Miguel-Ángel López-Nevot, Francisco Ruiz-Cabello, et al.
Pharmacological Research|December 28, 2020
Prevention and management of idiosyncratic drug-induced liver injury: Systematic review and meta-analysis of randomised clinical trialsHao Niu, Judith Sanabria-Cabrera, Ismael Alvarez-Alvarez, et al.
Frontiers in Pharmacology|February 2, 2012
Trends in qualifying biomarkers in drug safety. Consensus of the 2011 meeting of the spanish society of clinical pharmacologyJosé A G Agúndez, Jaime Del Barrio, Teresa Padró, et al.
Antiviral Therapy|July 22, 2006
Vascular ophthalmological side effects associated with antiviral therapy for chronic hepatitis C are related to vascular endothelial growth factor levelsRaúl J Andrade, F Jesús González, Luis Vázquez, et al.
Acta Pharmaceutica Sinica. B|January 13, 2022
Preclinical models of idiosyncratic drug-induced liver injury (iDILI): Moving towards predictionAntonio Segovia-Zafra, Daniel E Di Zeo-Sánchez, Carlos López-Gómez, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|May 16, 2026
HLA-B*44 Alleles and HLA-DQA1*03:01 as Genetic Risk Factors for Drug-Induced Liver Injury due to FluoroquinolonesPaola Nicoletti, M Isabel Lucena, Raul J Andrade, et al.
Plos One|April 16, 2014
Selected ABCB1, ABCB4 and ABCC2 polymorphisms do not enhance the risk of drug-induced hepatotoxicity in a Spanish cohortEugenia Ulzurrun, Camilla Stephens, Francisco Ruiz-Cabello, et al.
Plos One|October 17, 2015
Correction: Selected ABCB1, ABCB4 and ABCC2 Polymorphisms Do Not Enhance the Risk of Drug-Induced Hepatotoxicity in a Spanish CohortEugenia Ulzurrun, Camilla Stephens, Francisco Ruiz-Cabello, et al.
Pageof 16

Showing results (71-80 of 152) with videos related to

Sort By:
Pageof 16
Expert Opinion on Drug Metabolism & Toxicology|September 15, 2022
Modeling drug-induced liver injury: current status and future prospectsDaniel E Di Zeo-Sánchez, Antonio Segovia-Zafra, Gonzalo Matilla-Cabello, et al.
Hepatology (Baltimore, Md.)|June 16, 2011
The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injuryAyako Suzuki, Elizabeth M Brunt, David E Kleiner, et al.
Plos One|July 23, 2013
HLA alleles influence the clinical signature of amoxicillin-clavulanate hepatotoxicityCamilla Stephens, Miguel-Ángel López-Nevot, Francisco Ruiz-Cabello, et al.
Pharmacological Research|December 28, 2020
Prevention and management of idiosyncratic drug-induced liver injury: Systematic review and meta-analysis of randomised clinical trialsHao Niu, Judith Sanabria-Cabrera, Ismael Alvarez-Alvarez, et al.
Frontiers in Pharmacology|February 2, 2012
Trends in qualifying biomarkers in drug safety. Consensus of the 2011 meeting of the spanish society of clinical pharmacologyJosé A G Agúndez, Jaime Del Barrio, Teresa Padró, et al.
Antiviral Therapy|July 22, 2006
Vascular ophthalmological side effects associated with antiviral therapy for chronic hepatitis C are related to vascular endothelial growth factor levelsRaúl J Andrade, F Jesús González, Luis Vázquez, et al.
Acta Pharmaceutica Sinica. B|January 13, 2022
Preclinical models of idiosyncratic drug-induced liver injury (iDILI): Moving towards predictionAntonio Segovia-Zafra, Daniel E Di Zeo-Sánchez, Carlos López-Gómez, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|May 16, 2026
HLA-B*44 Alleles and HLA-DQA1*03:01 as Genetic Risk Factors for Drug-Induced Liver Injury due to FluoroquinolonesPaola Nicoletti, M Isabel Lucena, Raul J Andrade, et al.
Plos One|April 16, 2014
Selected ABCB1, ABCB4 and ABCC2 polymorphisms do not enhance the risk of drug-induced hepatotoxicity in a Spanish cohortEugenia Ulzurrun, Camilla Stephens, Francisco Ruiz-Cabello, et al.
Plos One|October 17, 2015
Correction: Selected ABCB1, ABCB4 and ABCC2 Polymorphisms Do Not Enhance the Risk of Drug-Induced Hepatotoxicity in a Spanish CohortEugenia Ulzurrun, Camilla Stephens, Francisco Ruiz-Cabello, et al.
Pageof 16